Literature DB >> 26433922

Enhancing vaccine safety capacity globally: A lifecycle perspective.

Robert T Chen1, Tom T Shimabukuro2, David B Martin3, Patrick L F Zuber4, Daniel M Weibel5, Miriam Sturkenboom5.   

Abstract

Major vaccine safety controversies have arisen in several countries beginning in the last decades of 20th century. Such periodic vaccine safety controversies are unlikely to go away in the near future as more national immunization programs mature with near elimination of target vaccine-preventable diseases that result in relative greater prominence of adverse events following immunizations, both true reactions and temporally coincidental events. There are several ways in which vaccine safety capacity can be improved to potentially mitigate the impact of future vaccine safety controversies. This paper aims to take a "lifecycle" approach, examining some potential pre- and post-licensure opportunities to improve vaccine safety, in both developed (specifically U.S. and Europe) and low- and middle-income countries.
Copyright © 2015 American Journal of Preventive Medicine. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  AEFI; Capacity building; LMICs; Sustainability; Vaccine safety

Mesh:

Substances:

Year:  2015        PMID: 26433922      PMCID: PMC4663114          DOI: 10.1016/j.vaccine.2015.06.073

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  112 in total

1.  Injection safety: a global challenge.

Authors:  Y J Hutin; R T Chen
Journal:  Bull World Health Organ       Date:  1999       Impact factor: 9.408

Review 2.  The introduction of new vaccines into developing countries.

Authors:  R T Mahoney; J E Maynard
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

Review 3.  Perspectives on the design and analysis of prelicensure trials: bridging the gap to postlicensure studies.

Authors:  S Black
Journal:  Clin Infect Dis       Date:  2001-12-15       Impact factor: 9.079

4.  Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination.

Authors:  M T Niu; D E Erwin; M M Braun
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

5.  Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.

Authors:  Ana Szarfman; Stella G Machado; Robert T O'Neill
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Outbreak of aseptic meningitis associated with mass vaccination with a urabe-containing measles-mumps-rubella vaccine: implications for immunization programs.

Authors:  I Dourado; S Cunha; M G Teixeira; C P Farrington; A Melo; R Lucena; M L Barreto
Journal:  Am J Epidemiol       Date:  2000-03-01       Impact factor: 4.897

7.  Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.

Authors:  Vitali Pool; M Miles Braun; John M Kelso; Gina Mootrey; Robert T Chen; John W Yunginger; Robert M Jacobson; Paul M Gargiullo
Journal:  Pediatrics       Date:  2002-12       Impact factor: 7.124

8.  The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI).

Authors:  Jan Bonhoeffer; Katrin Kohl; Robert Chen; Philippe Duclos; Harald Heijbel; Ulrich Heininger; Tom Jefferson; Elisabeth Loupi
Journal:  Vaccine       Date:  2002-12-13       Impact factor: 3.641

9.  Does influenza vaccination exacerbate asthma? Analysis of a large cohort of children with asthma. Vaccine Safety Datalink Team.

Authors:  P Kramarz; F DeStefano; P M Gargiullo; R L Davis; R T Chen; J P Mullooly; S B Black; H R Shinefield; K Bohlke; J I Ward; M S Marcy
Journal:  Arch Fam Med       Date:  2000-07

10.  Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

Authors:  Weigong Zhou; Vitali Pool; John K Iskander; Roseanne English-Bullard; Robert Ball; Robert P Wise; Penina Haber; Robert P Pless; Gina Mootrey; Susan S Ellenberg; M Miles Braun; Robert T Chen
Journal:  MMWR Surveill Summ       Date:  2003-01-24
View more
  13 in total

1.  Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.

Authors:  Hazel J Clothier; Nigel W Crawford; Melissa Russell; Heath Kelly; Jim P Buttery
Journal:  Drug Saf       Date:  2017-06       Impact factor: 5.606

2.  Tracking the progress in COVID-19 and vaccine safety research - a comprehensive bibliometric analysis of publications indexed in Scopus database.

Authors:  Tosin Yinka Akintunde; Shaojun Chen; Taha Hussein Musa; Felix Oluseyi Amoo; Adekunle Adedeji; Elhakim Ibrahim; Angwi Enow Tassang; Idriss Hussein Musa; Hassan Hussein Musa
Journal:  Hum Vaccin Immunother       Date:  2021-10-06       Impact factor: 4.526

Review 3.  Vaccine Safety and Surveillance for Adverse Events Following Immunization (AEFI) in India.

Authors:  Jyoti Joshi; Manoja Kumar Das; Deepak Polpakara; Satinder Aneja; Mahesh Agarwal; Narendra Kumar Arora
Journal:  Indian J Pediatr       Date:  2017-11-23       Impact factor: 5.319

4.  Value of an in-depth analysis of unpublished data on the safety of influenza vaccines in pregnant women.

Authors:  Neal A Halsey; Tina Proveaux
Journal:  Vaccine       Date:  2017-09-27       Impact factor: 3.641

5.  Retrospective study of immunization errors reported in an online Information System.

Authors:  Tânia Cristina Barboza; Rafael Alves Guimarães; Fernanda Raphael Escobar Gimenes; Ana Elisa Bauer de Camargo Silva
Journal:  Rev Lat Am Enfermagem       Date:  2020-06-19

6.  A Novel Structure of Blockchain Applied in Vaccine Quality Control: Double-Chain Structured Blockchain System for Vaccine Anticounterfeiting and Traceability.

Authors:  Zehuan Qiu; Yifan Zhu
Journal:  J Healthc Eng       Date:  2021-03-19       Impact factor: 2.682

7.  Use of electronic immunization registry in the surveillance of adverse events following immunization.

Authors:  Ana Paula Sayuri Sato; Vinícius Leati de Rossi Ferreira; Márcia de Cantuária Tauil; Laura Cunha Rodrigues; Mariana Bernardes Barros; Edmar Martineli; Ângela Aparecida Costa; Marta Inenami; Eliseu Alves Waldman
Journal:  Rev Saude Publica       Date:  2018-02-05       Impact factor: 2.106

8.  Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000-2015.

Authors:  Jiayao Lei; Madhava Ram Balakrishnan; Jane F Gidudu; Patrick L F Zuber
Journal:  Vaccine       Date:  2018-02-14       Impact factor: 3.641

9.  A Prospective Cohort Study on the Safety of Infant Pentavalent (DTwP-HBV-Hib) and Oral Polio Vaccines in Two South Indian Districts.

Authors:  Narendra Kumar Arora; Manoja Kumar Das; Ramesh Poluru; Neeraj Kumar Kashyap; Thomas Mathew; John Mathai; Mahesh Kumar Aggarwal; Pradeep Haldar; Thomas Verstraeten; Patrick L F Zuber
Journal:  Pediatr Infect Dis J       Date:  2020-05       Impact factor: 3.806

10.  A self-aggregating peptide: implications for the development of thermostable vaccine candidates.

Authors:  Adolfo Cruz-Reséndiz; Jesús Zepeda-Cervantes; Alicia Sampieri; Carlos Bastián-Eugenio; Gonzalo Acero; J Iván Sánchez-Betancourt; Goar Gevorkian; Luis Vaca
Journal:  BMC Biotechnol       Date:  2020-01-21       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.